The penny shares I’m taking a look at immediately have one thing in widespread. There are just one or two analysts providing suggestions I can discover, however no less than they’re all bullish. That’s one of many dangers we face with penny shares. There’s typically little or no analysis on the market for us to make use of, and we may be largely on our personal.

Medical gadgets

Creo Medical Group (LSE: CREO) makes medical devices for surgical endoscopy, utilizing microwave and radio frequencies. Minimally-invasive surgical procedure can expose sufferers to much less hazard, and cut back prices.

However after a formidable begin to inventory market life, the Creo share price collapsed. Up to now 5 years, it’s crashed 89%. The shares are down to 18p for a market capitalisation of £73m.

Creo‘s been one of those promising growth stock candidates we see so often. But it’s but to make an annual revenue. And forecasts recommend that’s nonetheless unlikely to occur by 2026. However no less than they present the losses falling steadily.

Steadiness sheet enhance

I see indicators that 2025 could possibly be the 12 months that issues change. In September, a brand new share subject raised £12m, so we’ve already had some dilution. With interim outcomes the identical month, CEO Craig Gulliford mentioned: “The launch of Speedboat UltraSlim in late 2023, our smallest device to date, was a significant milestone and helped us to achieve record core product sales for H1-2024.”

That appears key to me. Will this new expertise result in earnings within the nick of time? Or will the corporate want to return to the market to lift extra cash? It might all hinge on that. For traders who can deal with the concern of money working low once more, I believe Creo’s value contemplating for its progress potential.

Sensible sensing

Oxford Metrics (LSE: OMG) is worthwhile, with a powerful steadiness sheet. The 2024 full 12 months appears to be like prefer it was a tricky one, with adjusted earnings per share falling 44% to five.29p. Internet money at 30 September, although wholesome at £50.7m, declined 22%.

The corporate makes sensible sensing and motion-capture expertise. Its Vicon product is utilized in sports activities, schooling, movie manufacturing, digital actuality and biomedical research. And it has a formidable record of shoppers, together with Boeing and Ford.

However the share price is down 55% over 5 years, with most of that previously 12 months. It’s down to 51p on the time of writing, for a market-cap of £65m. After a poor efficiency like that, why am I optimistic about Oxford Metrics?

Trying forward

With these disappointing 2024 outcomes, CEO Imogen O’Connor identified that they need to be seen “against an exceptionally strong prior year comparator where our teams delivered more camera systems than ever before.”

And in terms of the 2025 outlook, the full-year replace spoke of “a good spread of opportunities across all main markets and a pipeline of new products”.

There’s clearly a danger of one other painful 12 months. However forecasts (although solely from a few brokers) point out a return to earnings progress and put a 97p goal price on the inventory. That has to make it value additional research.